Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Providence Health & Services
Robert W. Franz Cancer Center
Providence Cancer Center
Providence Cancer Center, Earle A. Chiles Research Institute
MedImmune LLC
Information provided by (Responsible Party):
Providence Health & Services Identifier:
First received: May 22, 2013
Last updated: September 4, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2023
  Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)